These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1106 related items for PubMed ID: 27282621

  • 1. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N, Svensson AM, Miftaraj M, Franzén S, Zethelius B, Eliasson B, Gudbjörnsdottir S.
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L.
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [Abstract] [Full Text] [Related]

  • 6. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS.
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
    Lee SJ, Ha KH, Lee JH, Lee H, Kim DJ, Kim HC.
    PLoS One; 2019 Mar; 14(2):e0211959. PubMed ID: 30742667
    [Abstract] [Full Text] [Related]

  • 9. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
    Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nyström T, Norhammar A.
    Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
    Chan CW, Yu CL, Lin JC, Hsieh YC, Lin CC, Hung CY, Li CH, Liao YC, Lo CP, Huang JL, Lin CH, Wu TJ.
    Cardiovasc Diabetol; 2018 Jan 24; 17(1):20. PubMed ID: 29368615
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.
    Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ.
    Diabetes Obes Metab; 2014 Oct 24; 16(10):977-83. PubMed ID: 24762119
    [Abstract] [Full Text] [Related]

  • 14. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT, Chang KC, Li CY, Wu JS.
    Cardiovasc Diabetol; 2016 Mar 01; 15():41. PubMed ID: 26932742
    [Abstract] [Full Text] [Related]

  • 15. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
    Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T.
    Diabetes Obes Metab; 2014 Dec 01; 16(12):1247-56. PubMed ID: 25109825
    [Abstract] [Full Text] [Related]

  • 16. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
    Ou HT, Chang KC, Li CY, Wu JS.
    Br J Clin Pharmacol; 2017 Jul 01; 83(7):1556-1570. PubMed ID: 28109184
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH, Kim B, Choi H, Kim DJ, Kim HC.
    Diabet Med; 2017 Sep 01; 34(9):1235-1243. PubMed ID: 28523719
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH, Yin H, Azoulay L.
    Can J Diabetes; 2015 Oct 01; 39(5):383-9. PubMed ID: 25840943
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.